Supplementary Data 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma | Synapse
July 17, 2024
Supplementary Data 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
Individual whole slide images of HNSCC PDX tumor used for TME analysis.